Diffuse Large B-Cell Lymphoma Prognosis Calculator

What This Calculator Does

This tool estimates the prognosis for diffuse large B-cell lymphoma (DLBCL) by combining key clinical factors into a validated scoring system. It provides a risk category and estimated survival outlook based on the International Prognostic Index (IPI) or the revised IPI (R-IPI), depending on the input variables used.

The calculator is intended for healthcare professionals to support clinical decision-making and patient discussions. It is not a substitute for comprehensive medical assessment.

How the Prognosis Is Calculated

The prognosis estimate is derived from the International Prognostic Index, a widely validated clinical tool developed for DLBCL. The index assigns one point for each of the following risk factors:

• Age – greater than 60 years
• Lactate dehydrogenase (LDH) – elevated above normal
• Performance status – ECOG score of 2 or higher
• Disease stage – Ann Arbor stage III or IV
• Extranodal involvement – more than one extranodal site

The total score (0 to 5) determines the risk group. The calculator then maps this score to the corresponding 5-year overall survival estimate and progression-free survival data from published clinical studies.

If the revised IPI (R-IPI) is selected, the same five factors are used but the risk groups are reclassified into three categories instead of four, reflecting more contemporary treatment outcomes.

Understanding Your Results

The output includes the total IPI score, the risk category, and the estimated 5-year overall survival rate. These numbers are based on large cohort studies and represent population-level statistics, not individual predictions.

Risk categories for the standard IPI:

• Low risk (score 0–1) – approximately 73% 5-year overall survival
• Low-intermediate risk (score 2) – approximately 51% 5-year overall survival
• High-intermediate risk (score 3) – approximately 43% 5-year overall survival
• High risk (score 4–5) – approximately 26% 5-year overall survival

Risk categories for the revised IPI (R-IPI):

• Very good risk (score 0) – approximately 94% 4-year progression-free survival
• Good risk (score 1–2) – approximately 80% 4-year progression-free survival
• Poor risk (score 3–5) – approximately 53% 4-year progression-free survival

These estimates reflect outcomes with rituximab-containing chemotherapy regimens (R-CHOP or equivalent). Results should be interpreted in the context of the patient's overall clinical picture, including comorbidities, histologic subtype, and treatment plan.

Common Mistakes When Using This Tool

• Using incorrect LDH reference ranges – LDH must be compared to the local laboratory's upper limit of normal. Using absolute values without normalization can produce an incorrect score.
• Misclassifying ECOG performance status – ECOG 2 or higher means the patient is bedridden for more than 50% of the day. Overestimating or underestimating functional status changes the score.
• Counting extranodal sites incorrectly – Only sites of involvement beyond the primary lymph node region count. Bone marrow, liver, and lung are common extranodal sites, but each must be confirmed by imaging or biopsy.
• Applying the IPI to transformed lymphoma – The IPI was validated for de novo DLBCL. Its accuracy in transformed indolent lymphoma is less established.
• Treating the estimate as an individual prognosis – The IPI provides group-level risk stratification. Individual outcomes vary widely within each risk category.

Limitations and Important Considerations

The IPI and R-IPI were developed using data from clinical trials and registry studies. Several factors may affect the accuracy of the estimate for a specific patient:

• Treatment era – The original IPI was developed before rituximab became standard. The R-IPI and subsequent validations account for rituximab-based therapy, but outcomes continue to improve with newer regimens.
• Cell of origin – The IPI does not incorporate molecular subtype (germinal center B-cell vs. activated B-cell), which carries independent prognostic significance.
• Double-hit or triple-hit genetics – MYC and BCL2 rearrangements confer a worse prognosis that the IPI may not fully capture.
• Comorbidities and frailty – The IPI does not account for organ function, performance status beyond ECOG, or treatment tolerability.
• Population differences – The original validation cohorts were predominantly treated in academic centers. Outcomes may differ in community practice or specific demographic groups.

This calculator should be used as one component of a broader prognostic assessment, not as the sole basis for treatment decisions.

Practical Use Cases

• Initial risk stratification – Quickly categorize a newly diagnosed DLBCL patient into a risk group to guide treatment intensity and clinical trial eligibility.
• Patient counseling – Provide patients and families with a general understanding of expected outcomes based on population data.
• Treatment planning discussions – Support conversations about whether to escalate or de-escalate therapy, particularly in older or frail patients.
• Clinical documentation – Record the IPI score as part of the standard diagnostic workup for DLBCL, which is recommended by major oncology guidelines.